Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.

Abstract

The immunogenicity and safety of a new recombinant hepatitis B vaccine from the Instituto Butantan (Butang) were evaluated in a multicenter, double-blind, prospective equivalence study in three centers in Brazil. Engerix B was the standard vaccine. A total of 3937 subjects were recruited and 2754 (70%) met all protocol criteria at the end of the study. All… (More)

Topics

2 Figures and Tables

Cite this paper

@article{Martins2004MulticenterSO, title={Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.}, author={Reinaldo de Menezes Martins and Gilberta Bensabath and Luiz Cl{\'a}udio Arraes and Maria de Lourdes Aguiar Oliveira and Juliana Cust{\'o}dio Miguel and Glayse Glayde Barbosa and Luiz Ant{\^o}nio Bastos Camacho}, journal={Memorias do Instituto Oswaldo Cruz}, year={2004}, volume={99 8}, pages={865-71} }